Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents

Molecules

Volumn 14, Issue 2, 2009, Pages 633-654

  Prokai Tatrai, Katalin ^a   Prokai, Laszlo ^a  

^a UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Analogue; CNS delivery; Neuropeptide; Prodrug; Prodrug amenable analogue; TRH

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL STIMULANT AGENT; PEPTIDE; PRODRUG; PROTIRELIN;

ANIMAL; ANIMAL BEHAVIOR; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG STABILITY; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG STABILITY; MOLECULAR STRUCTURE; PEPTIDES; PRODRUGS; THYROTROPIN-RELEASING HORMONE;

EID: 61449207912     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules14020633     Document Type: Review

References (70)

1. Begley, D.J.; Brightman, M.W. In Progress in Drug Research; Prokai, L., Prokai-Tatrai, K., Eds.; Birkhauser: Basel, Switzerland, 2003; Vol. 61, Chapter 2, pp. 39-78.
2. Brownlees, J.; Williams, C.H. Peptidases, Peptides, and the Mammalian Blood-Brain Barrier. J. Neurochem. 1993, 60, 793-803.
3. Tatsuta, T.; Naito, M.; Oh-Hara, T.; Sugawara, I.; Tsuruo, T. Functional Involvement of P-glycoprotein in Blood-Brain Barrier. J. Biol. Chem. 1992, 28, 20383-20391.
4. Golden, P.L.; Pardridge, W.M. Brain Microvascular P-glycoprotein and a Revised Model of Multidrug Resistance in Brain. Cell Mol. Neurobiol. 2000,20, 165-181.
5. Taylor, E.M. The Impact of Efflux Transporters in the Brain on the Development of Drugs for CNS Disorders. Clin. Pharmacokinet. 2002, 41, 81-92.
6. Temsamani, J.; Scherrmann, J.M.; Reesa, A. R.; Kaczore, M. Brain Drug Delivery Technologies: Novel Approaches for Transporting Therapeutics. Pharm. Sci. Technolo. Today 2000, 3, 155-162.
7. Fortin, D. In Progress in Drug Research; Prokai, L.; Prokai-Tatrai, K., Eds.; Birkhauser: Basel, Switzerland, 2003; Vol. 61, Chapter 4, pp. 125-154.
8. Pardridge, W.M.; Eisenberg, J.; Yamada, T. Human Blood-Brain Barrier Insulin Receptor. J. Neurochem. 1985, 44, 1171-1178.
9. Tsuji, A. Small Molecular Drug Transfer Across the Blood-Brain Barrier via Carrier-Mediated Transport Systems. NeuroRx 2005, 7, 54-62.
10. Pardridge, W.M. Blood-Brain Barrier Delivery of Protein and Non-Viral Gene Therapeutics with Molecular Trojan Horses. J. Controll. Release 2007, 722, 345-348.
11. Kreuter, J. Application of Nanoparticles for the Delivery of Drugs to the Brain. Int. Congress Series 2005, 7277, 85-94.
12. Huynh, G.H.; Deen, D. F.; Szoka, F.C Barriers to Carrier Mediated Drug and Gene Delivery to Brain. J. Controll. Release 2006, 110, 236-259.
13. Albert, A. Chemical Aspects of Selective Toxicity. Nature 1958, 182, 421-423.
14. Anand, B.S.; Dey, S.; Mitra, A.K. Current Prodrug Strategies via Membrane Transporters/Receptors. Exp. Opin. Ther. Biol. 2002, 2, 607-620.
15. Levin, V.A. Relationship of Octanol/Water Partition Coefficient, and Molecular Weight to Rat Brain Capillary Permeability. J. Med. Chem. 1980, 23, 682-684.
16. Partridge, W.M. Blood-Brain Barrier Biology, and Methodology. J. Neurovirol. 2000, J. 556-569.
17. Abraham, M.H.; Chadha, H.S.; Mitchell, R.C. Hydrogen-Bonding. Part 36. Determination of Blood Brain Distribution Using Octanol-Water Partition Coefficients. Drug Dis. Discov. 1995, 13, 123-131.
18. Habgood, M.D.; Begley, D.J.; Abbott, N.J. Determination of Passive Drug Entry into the Central Nervous System. Cell Mol. Neurobiol. 2000, 20, 231-253.
19. Banks, W.A.; Kastin, A.J. Peptides and the Blood-Brain Barrier: Lipophilicity as a Predictor of Permeability. Brain Res. Bull. 1985, 75, 287-292.
20. Hansch, C.; Björkroth, J.P.; Leo, A. Hydrophobicity and Central Nervous System Agents: On the Principle of Minimal Hydrophobicity in Drug Design. J. Pharm. Sci. 1987, 76, 663-687.
21. Tatsuta, T.; Naito, M.; Oh-Hara, T.; Sugawara, I.; Tsuruo, T. Functional Involvement of Pglycoprotein in Blood-Brain Barrier. J. Biol. Chem. 1992, 28, 20383-20391.
22. Bak, A.; Gudmundsson, O.S.; Friis, GJ.; Shiahaan, T.J.; Borchardt, R.T. Acyloxy-Alkoxy-Based Cyclic Prodrugs of Opioid Peptides: Evaluation of the Chemical and Enzymatic Stability as well as Their Transport Properties Across Caco-2 Cell Monolayers. Pharm. Res. 1999, 16, 24-29.
23. Begley, D. J. The Blood-Brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System. J. Pharm. Pharmacol. 1996, 48, 136-146.
24. Prokai, L.; Prokai-Tatrai, K.; Ouyang, X.; Kim, H.S.; Wu, W.M.; Zharikova, A.D.; Bodor, N. Metabolism-Based Brain-Targeting System for a Thyrotropin-Releasing Hormone Analogue. J. Med. Chem. 1999, 42, 4563-4571.
25. Prokai, L.; Prokai-Tatrai, K.; Bodor, N. Targeting Drugs to the Bain by Redox Chemical Delivery Systems. Med. Res. Rev. 2000, 20, 367-416.
26. Bodor, N.; Farag, H.H.; Brewster, M. E. Site-Specific, Sustained Release of Drugs to the Brain. Science 1981, 214, 1370-1372.
27. Zlokovic, B.V.; Segal, M.B.; Begley, D.J.; Davson, H.; Rakic, L. Permeability of the BloodCerebrospinal Fluid and the Blood-Brain Barriers to Thyrotropin-Releasing Hormone. Brain Res. 1985, 358, 191-199.
28. Prokai, L. In Progress in Drug Research; Jucker, E. Ed.; Birkhauser: Basel, Switzerland, 2002; Vol. 59, Chapter 5, pp. 133-170.
29. Schally, A.V.; Bowers, C.Y.; Redding, T.W.; Barrett, J.F. Isolation of Thyrotropin Releasing Factor (TRF) from Porcine Hypothalamus. Biochem. Biophys. Res. Commun. 1966, 25, 165-169.
30. Böler, J.; Enzmann, F.; Folkers, K.; Bowes, C.Y.; Schally, A.V. The Identity of Chemical and Hormonal Properties of the Thyrotropin Releasing Hormone and Pyroglutamyl-Histidyl-Proline Amide. Biochem. Biophys. Res. Commun. 1969, 37, 705-710.
31. Griffiths, E.C. Thyrotropin Releasing Hormone: Endocrine and Central Effects. Psychoneuroendocrinology 1985, 10, 225-235.
32. Takeuchi, Y.; Matsushita, H.; Kawano, H.; Sakai, H.; Yoshimoto, K.; Sawada,T. TRH Increases Cerebrospinal Fluid Concentration of Kynurenine. Neuroreport 1999,10, 3601-3603.
33. Breese, G.; Cott, J.; Cooper, B.; Prange, A.; Lippton, M.; Plotnikoff, N. Effects of ThyrotropinReleasing Hormone (TRH) on Actions of Actions of Pentobarbital and Other Centrally Active Drugs. J. Pharmacol. Exp. Ther. 1975, 193, 11-22.
34. Hinkle, P.M.; Pekary, A.E.; Senanayaki, S.; Sattin, A. Role of TRH Receptors as Possible Mediators of Analeptic Actions of TRH-Like Peptides. Brain Res. 2002, 935, 59-64.
35. Schmidt, D. Effects of Thyrotropin Releasing Hormone (TRH) on Pentobarbital-Induced Decrease in Cholinergic Neuronal Activity. Commun. Psychopharm. 1977, 7, 469-473.
36. Miyamoto, M.; Nagai, Y.; Narumi, S.; Saji, Y.; Nagawa, Y. TRH and its Novel Analog (DN-1417): Antipentobarbital Action and Involvement of Cholinergic Mechanisms. Pharmacol. Biochem. Behav. 1982, 77, 797-806.
37. Bassiri, R. M.; Utiger, R.D. Metabolism and Excretion of Exogenous Thyrotropin-Releasing Hormone in Humans. J. Clin. Invest. 1981, 52, 1616-1619.
38. Redding, T.W.; Schally, A.V. On the Half Life of Thyrotropin-Releasing Hormone in Rats. Neuroendocrinology 1972, 9, 250-256.
39. Kelly, J.A.; Slator, G.R.; Tipton, K.F.; Williams, C.H.; Karl Bauer. Kinetic Investigation of the Specificity of Porcine Brain Thyrotropin-Releasing Hormone-Like Peptides. J. Biol. Chem. 2000, 275, 16746-16751.
40. Zlokovic, B.V.; Segal, M.B.; Begley, D.J.; Davson, H.; Rakic, L. Permeability of the BloodCerebrospinal Fluid and the Blood-Brain Barriers to Thyrotropin-Releasing Hormone. Brain Res. 1985, 358, 191-199.
41. Pekary, A.E.; Sattina A.; Meyerhoff, J.L.; Chilingar, M. Valproate Modulates TRH Receptor, TRH and TRH-like Peptide Levels in Rat Brain. Peptides 2004, 25, 647-658.
42. Szirtes, T.L.; Kisfaludi, L.; Palosi, E.; Szporny, L. Synthesis of Thyrotropin-Releasing Hormone Analogues. 1. Complete Dissociation of Central Nervous System Effect from ThyrotropinReleasing Activity. J. Med. Chem. 1984, 27, 741-745.
43. Nillni, E.A.; Sevarino, K.A. The Biology of Pro-Thyrotropin-Releasing Hormone-Derived Peptides. Endocr. Rev. 1999, 20, 599-648.
44. Stenly Jr., S.; Prokai-Tatrai, K.; Prokai, L. Rapid Screening of Combinatorial Libraries by Mass Spectrometry: A Novel Approach for Monitoring Substrate Specificity of Enzymes. Anal. Chem. 2005, 7, 698-701.
45. Fischer, W.; Spiess, J. Identification of a Mammalian Glutaminyl Cyclase Converting Glutaminyl into Pyroglutaminyl Peptides. Proc. Natl. Acad. Sci. USA 1987, 84, 3628-3632
46. Lambeir, A.M.; Durinx, C.; Schärpe, S.; De Meester, I. Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV. Crit. Rev. Clin. Lab. Sci., 2003, 40, 209-294.
47. Polgar, L. Structure-Function of Prolyl Oligopeptidase and its Role in Neurological Disorders. Curr. Med. Chem. CNS Agents 2002, 2, 251-257.
48. Kenny, A. J.; Booth, A. G.; George, S. G.; Ingram, J.; Kershaw, D.; Wood, E. J.; Young, A. R. Dipeptidyl Peptidase IV, a Kidney Brush-Border Serine Peptidase. Biochem. J. 1976, 757, 169-82
49. Prokai-Tatrai, K.; Prokai, L.; Bodor, N. Brain-Targeted Delivery of a Leucine-Enkephalin Analogue by Retrometabolic Design. J. Med. Chem. 1996, 39, 4775-4782.
50. Prokai-Tatrai, K.; Kim, H.S.; Prokai. L. The Utility of Oligopeptidase in Brain-Targeting Delivery of an Enkephalin Analogue by Prodrug Design. Open Med. Chem. J. 2008, 2, 97-100.
51. Code, S. M.; Aitken, A.; Beg, F.; Smyth, D.G. A Novel Peptide, Pyroglutamylglutamylproline, in the Rabbit Prostate Complex Structurally Related to Thyrotropin-Releasing Hormone. J. Biol. Chem. 1989, 264, 7788-7791.
52. Rondeel, J.M.M.; Klootwijk, W.; Linkels, E.; van de Greef, WJ.; Visser, T. Neural Differentiation of the Human Neuroblastoma Cell-Line IMR32 Induces Production of a Thyrotropin-Releasing Hormone-Like Peptide. Brain Res. 1994, 665, 262-268.
53. Pekary, A.E.; Meyerhoff, J. L.; Sattin, A. Electroconvulsive Seizures Modulate Levels of Thyrotopin Releasing Hormone and Related Peptides in Rat Hypothalamus, Cingulate and Lateral Cerebellum. Brain Res. 2000, 884, 174-183.
54. 2 Bioorg. Med. Chem. Lett. 2003, 13, 1011-1014.
55. Ong, S.W.; Liu, H.L.; Pidgeon, C. Immobilized-Artificial-Membrane Chromatography: Measurements of Membrane Partition Coefficient and Predicting Drug Membrane Permeability. J. Chromatogr. A 1996, 728, 113-128.
56. Braddy, A.C.; Janáky, T.; Prokai, L. Immobilized Artificial Membrane Chromatography Coupled with Atmospheric Pressure Ionization Mass Spectrometry. J. Chromatogr. A 2002, 966, 81-87.
57. Prokai, L.; Zharikova, A.D.; Janáky, T.; Li, X. Braddy, A.C.; Perjési, P.; Matveeva, L.; Powell, D.H.; Prokai-Tatrai, K. Integration of Mass Spectrometry into Early-Phase Discovery and Development of Central Nervous System Agents. J. Mass. Spectrom. 2001, 36, 1211-1219.
58. Lipinski, C.A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Setting. Adv. Drug Deliv. Rev. 1997, 23, 3-26.
59. Moriguchi, I.; Hirono, S.; Liu, Q; Nakagome, I.; Matsushita, Y. Simple Method of Calculating Octanol/Water Partition Coefficients. Chem. Pharm. Bull. 1992,40, 127-130.
60. Rivier, J., Burgus, R., Vale, W., Ling, N., Monahan, M. Synthetic Thyrotropin-Releasing Factor Analogs. 3. Effect of Replacement or Modification of Histidine Residue on Biological-Activity. J. Med. Chem. 1972, 75, 479-482.
61. Prokai-Tatrai, K.; Perjesi, P.; Zharikova, A.D.; Li, X.; Prokai, L. Design, Synthesis and Biological Evaluation of Novel, Centrally-Acting Thyrotropin-Rleasin Hormone Analogues. Bioorg. Med. Chem. Lett. 2002, 72, 2111-2114.
62. Prokai, L.; Prokai-Tatrai, K.; Zharikova, A.D.; Nguyen, V.; Stevens, Jr, S.M. Centrally-Acting and Metabolically Stable Thyrotropin-Releasing Hormone Analogues by Replacement of Histidine with Substituted Pyridinium. J. Med. Chem. 2004, 47, 6025-6033.
63. Eda, M. E.; Kurth, M. J. Polymer Site-Site Interactions: Mechanistic Implication in the Solid-Phase Zincke Reaction. Chem. Commun. 2001, 723-724.
64. Ghose, A. K.; Pritchett, A.; Crippen, G. M. Atomic Physicochemical Parameters for 3-Dimensional Structure Directed Quantitative Structure-Activity-Relationships. 3. Modeling Hydrophobic Interactions. J. Comput. Chem. 1988, 9, 80-90.
65. Bodor, N.; Gabanyi, Z.; Wong, C. K. A New Method for the Estimation of Partition-Coefficient. J. Am. Chem. Soc. 1989, 111, 3783-3786. 67.
66. Buchwald, P.; Bodor, N. Octanol-Water Partition of Nonzwitterionic Peptides: Predictive Power of a Molecular Size-Based Model. Proteins 1998, 30, 86-99.
67. 2]TRH and its Chemical Brain Targeting System. Brain Res. 2002, 952, 268-214.
68. Brown, W. M. Taltirelin (Tanabe Seiyaku). IDrugs 2001 4, 1389-1400.
69. Prokai-Tatrai, K.; Teixido, M.; Nguyen, V.; Zharikova, A.D.; Prokai, L. A Pyridinium-Substituted Analogue of the TRH-Like Tripeptide pGlu-Glu-Pro-NH2 and its Prodrugs as Central Nervous System Agents. Med. Chem. 2005, 7, 141-152.
70. Porsolt, R.D.; Le Pichon, M.; Jalfre, M. Depression: A New Animal Model Sensitive to Antidepressant Treatment. Nature 1977, 266, 730-732.